These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12270193)

  • 1. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.
    Lynch CL; Hale JJ; Budhu RJ; Gentry AL; Mills SG; Chapman KT; MacCoss M; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Cascieri MA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA
    Bioorg Med Chem Lett; 2002 Oct; 12(20):3001-4. PubMed ID: 12270193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.
    Hale JJ; Budhu RJ; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano SJ; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini EA
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2997-3000. PubMed ID: 12270192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
    Hale JJ; Budhu RJ; Holson EB; Finke PE; Oates B; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano S; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini E
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2741-5. PubMed ID: 11591514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.
    Willoughby CA; Rosauer KG; Hale JJ; Budhu RJ; Mills SG; Chapman KT; MacCoss M; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Cascieri MA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA
    Bioorg Med Chem Lett; 2003 Feb; 13(3):427-31. PubMed ID: 12565944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.
    Lynch CL; Willoughby CA; Hale JJ; Holson EJ; Budhu RJ; Gentry AL; Rosauer KG; Caldwell CG; Chen P; Mills SG; MacCoss M; Berk S; Chen L; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Cascieri MA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA
    Bioorg Med Chem Lett; 2003 Jan; 13(1):119-23. PubMed ID: 12467630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.
    Hale JJ; Budhu RJ; Mills SG; MacCoss M; Malkowitz L; Siciliano S; Gould SL; DeMartino JA; Springer MS
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1437-40. PubMed ID: 11378372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
    Shankaran K; Donnelly KL; Shah SK; Guthikonda RN; MacCoss M; Mills SG; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Carella A; Carver G; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3419-24. PubMed ID: 15177445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives.
    Imamura S; Ishihara Y; Hattori T; Kurasawa O; Matsushita Y; Sugihara Y; Kanzaki N; Iizawa Y; Baba M; Hashiguchi S
    Chem Pharm Bull (Tokyo); 2004 Jan; 52(1):63-73. PubMed ID: 14709870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines.
    Lynch CL; Gentry AL; Hale JJ; Mills SG; MacCoss M; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Cascieri MA; Doss G; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA
    Bioorg Med Chem Lett; 2002 Feb; 12(4):677-9. PubMed ID: 11844699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
    McCombie SW; Tagat JR; Vice SF; Lin SI; Steensma R; Palani A; Neustadt BR; Baroudy BM; Strizki JM; Endres M; Cox K; Dan N; Chou CC
    Bioorg Med Chem Lett; 2003 Feb; 13(3):567-71. PubMed ID: 12565973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.
    Dorn CP; Finke PE; Oates B; Budhu RJ; Mills SG; MacCoss M; Malkowitz L; Springer MS; Daugherty BL; Gould SL; DeMartino JA; Siciliano SJ; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2001 Jan; 11(2):259-64. PubMed ID: 11206473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.
    Kim D; Wang L; Hale JJ; Lynch CL; Budhu RJ; Maccoss M; Mills SG; Malkowitz L; Gould SL; DeMartino JA; Springer MS; Hazuda D; Miller M; Kessler J; Hrin RC; Carver G; Carella A; Henry K; Lineberger J; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2129-34. PubMed ID: 15808483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
    Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
    Shiraishi M; Aramaki Y; Seto M; Imoto H; Nishikawa Y; Kanzaki N; Okamoto M; Sawada H; Nishimura O; Baba M; Fujino M
    J Med Chem; 2000 May; 43(10):2049-63. PubMed ID: 10821717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity.
    Lynch CL; Hale JJ; Budhu RJ; Gentry AL; Finke PE; Caldwell CG; Mills SG; MacCoss M; Shen DM; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Cascieri MA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini E
    Org Lett; 2003 Jul; 5(14):2473-5. PubMed ID: 12841758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
    Finke PE; Meurer LC; Oates B; Mills SG; MacCoss M; Malkowitz L; Springer MS; Daugherty BL; Gould SL; DeMartino JA; Siciliano SJ; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2001 Jan; 11(2):265-70. PubMed ID: 11206474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.
    Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
    Nishizawa R; Nishiyama T; Hisaichi K; Matsunaga N; Minamoto C; Habashita H; Takaoka Y; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2007 Feb; 17(3):727-31. PubMed ID: 17118654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes.
    Finke PE; Meurer LC; Oates B; Shah SK; Loebach JL; Mills SG; MacCoss M; Castonguay L; Malkowitz L; Springer MS; Gould SL; DeMartino JA
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2469-73. PubMed ID: 11549449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
    Palani A; Shapiro S; Clader JW; Greenlee WJ; Vice S; McCombie S; Cox K; Strizki J; Baroudy BM
    Bioorg Med Chem Lett; 2003 Feb; 13(4):709-12. PubMed ID: 12639564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.